News list

2013-06-03 | Press release

The funds managed by Edmond de Rothschild Investment Partners, BNP Paribas Développement and several managers of Reed Business Information France have completed the acquisition of the company

The Reed Elsevier Group has sold Reed Business Information France to Edmond de Rothschild Investment Partners (via the Winch Capital 2 fund), BNP Paribas Développement and several managers of the company.

Find out more

2013-05-29 | Press release

Edmond de Rothschild Investment Partners’ Winch Capital 2 fund has taken a stake in MCI, an international congress and event management company

With 47 offices in 23 countries and sales of CHF 337m in 2012, MCI is today a leading Professional Congress Organizer (PCO - organiser of scientific congresses for associations and institutionals) and a leading organizer of conferences and events for companies. The group has a strong presence in the pharmaceutical sector and an excellent image and reputation both for the quality of its service offer and its capacity to innovate and provide creative solutions. The group is also a model of employee shareholding schemes as close to 100 senior executives and managers own shares.

Find out more

2013-04-18 | Press release

Edmond de Rothschild Investment Partners co-leads the €15 Million Series A financing of Allecra Therapeutics with its new fund BioDiscovery 4

Edmond de Rothschild Investment Partners announces the first investment of BioDiscovery 4, its fourth fund dedicated to Life Sciences, through its participation in the Series A financing round of Allecra Therapeutics, which it co-leads with Forbion Capital Partners. EMBL Ventures is also part of the syndicate.

Find out more

2013-04-02 | Press release

SuperSonic Imagine Announces a Significant Financing Round, 28 million euros raised, FSI subscribes to half the round alongside historical investors and two new arrivals

SuperSonic Imagine, a French ultrasound company, is pleased to announce that it has raised €28 million with €14 million invested by the FSI (French Investment Fund) alongside two new investors, Alto Invest and KLSC (Kuwait Life Sciences Company) and a substantial subscription from their company’s historical investors.

Find out more

2013-03-12 | Press release

The funds managed by Edmond de Rothschild Investment Partners and BNP Paribas Développement supporting several key managers, enter into exclusive negotiation with Reed Elsevier for the acquisition of Reed Business Information France.

Reed Elsevier, the fund Winch Capital 2 managed by Edmond de Rothschild Investment Partners and BNP Paribas Développement have agreed to enter into an exclusive negotiation period in connection with the sale of Reed Business Information. The contemplated transaction will be soon submitted to the employees’ representatives of Reed Business Information SAS.

Find out more

2013-02-25 | Press release

Sapiens Attracts EUR 7.5 Million to Drive Development of Next Generation Deep Brain Stimulation Therapy

Find out more

2013-01-30 | Press release

Edmond de Rothschild Investment Partners celebrates its 10th anniversary with plans to raise EUR 500m over the next 4 years and to increase assets under management to EUR 1.3bn

Created from an existing activity within the group at the end of 2002, Edmond de Rothschild Investment Partners celebrates its 10th anniversary.

Find out more

2013-01-21 | Interview

Gilles Nobecourt on BioCentury TV: Winning investments in European Biotech

Find out more

2013-01-04 | Press release

GlycoVaxyn AG Signs Exclusive License Agreement with Janssen Pharmaceuticals

GlycoVaxyn AG, a leader in the development of innovative vaccines, today announced that Janssen Pharmaceuticals, Inc. (JPI), has signed an exclusive license agreement and entered a three-year research and development collaboration to develop a multi-valent bacterial vaccine employing GlycoVaxyn’s bio-conjugation technology.

Find out more

2012-12-19 | Press release

GlycoVaxyn AG Announces Strategic Collaboration with GSK

GlycoVaxyn AG, a leader in the development of innovative vaccines today announced a collaboration with GlaxoSmithKline Biologicals (GSK) to develop new bacterial vaccines employing GlycoVaxyn’s bio-conjugation technology.

Find out more

2012-11-08 | Press release

Edmond de Rothschild Investment Partners' Portfolio Company Vessix Vascular is acquired by Boston Scientific

Edmond de Rothschild Investment Partners announces that its portfolio company Vessix Vascular, Inc., which has developed a novel percutaneous radiofrequency balloon-catheter for renal denervation for the treatment of uncontrolled hypertension, has been acquired by Boston Scientific Corp. for up to $425M.

Find out more

2012-09-26 | Press release

NOXXON initiates Phase IIa Trial of Spiegelmer NOX-A12

Find out more

2012-09-06 | Press release

Edmond de Rothschild Investment Partners’ Winch Capital 2 fund helps DEFI become independent again

DEFI, the global N° 1 in spectacular outdoor advert ising (roof-top spectacular, digital signage and banners), has been bought back by the group’s historic shareholder, the Deodato family, with the assistance of Edmond de Rothschild Investment Partners’ Winch Capital 2 fund.

Find out more

2012-07-26 | Press release

Nexira is coming to India!

Nexira, a world leader and premier supplier of natural and innovative ingredients, is opening its 11th subsidiary in Mumbai, India, after having successfully opened sales offices in North & South America, Asia, Africa, Europe and Eastern Europe. The global growth strategy of the group is confirmed and India will play an important role.

Find out more

2012-07-11 | Communiqué de presse

Genkyotex Raises CHF25 Million in Series C Round Extension

Find out more

2012-07-10 | Press release

First closing and launch of BioDiscovery 4

Edmond de Rothschild Investment Partners is pleased to announce the first closing and launch of the fourth fund in its BioDiscovery franchise dedicated to investing in Life Sciences in France and in Europe.

Find out more